Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MAD study of NX210c in healthy elderly volunteers
NCT05827653Phase 1Completed
- Sponsor
- Axoltis Pharma
- Start
- Dec 2022
- Primary completion
- Apr 2023
- Modality
- Modified Peptides, Native Peptides
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of nx210c in Alzheimer's disease (AD) (4 cohorts), sponsored by Axoltis Pharma. Primary endpoint: Severity and incidence of treatment-emergent adverse events (TEAEs), serious adverse events (SAEs), suspected unexpected serious adverse reactions (SUSARs). Started Dec 2022; status: completed.
02
Drugs
nx210c
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT05827653.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05827653.